Clinical trials: Progressive Low-Grade Glioma
Low-Grade Glioma, Recurrent Low-Grade Glioma
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
- Conditions
- Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
- Trial name
- NCT04923126
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- St. Jude Children's Research Hospital
Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.
- Trial name
- NCT01734512
- Testing
- Everolimus
- Where
- 18 sites in United States
- Volunteers
- 65 people
- Sponsor
- University of California, San Francisco
Recurrent High-Grade Gliomas, Progressive Low-Grade Gliomas
ZD6474 to Treat Advanced Brain Cancer in Patients
Background: In vivo experiments have documented the ability of ZD6474 to inhibit tumor growth in various preclinical tumor models.
- Conditions
- Recurrent High-Grade Gliomas, Progressive Low-Grade Gliomas, Malignant Gliomas
- Trial name
- NCT00272350
- Testing
- Steroids, ZD6474
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG)
Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
The purpose of this study is to determine if a drug called sorafenib can shrink LGA tumors (low-grade astrocytomas) in children and adults.
- Conditions
- neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma
- Trial name
- NCT01338857
- Testing
- Sorafenib (Nexavar)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- NYU Langone Health